drugset / Trial / NCT04344444

Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease

NCT04344444 ↗

Phase 3 Terminated 22 enrolled LCMC Health
RandomizedParallel-groupOpen-labelTreatment

Summary

This study proposes to evaluate clinical outcomes and viral load in COVID-19 infected patients with early moderate and severe disease admitted to the hospital and randomized to one of three arms. Patients will be randomized to supportive care, OR hydroxychloroquine alone, OR hydroxychloroquine and azithromycin.

Timeline

Start
2020-04-13
Primary completion
2021-04-10
Completion
2022-01-05

Outcome

Outcome not reported

Stopped: “Lack of efficacy data from other studies”

Drugs

EvaluationDrugModalityDoseRoute
Subject Azithromycin Small molecule 250 mg Oral
Subject Hydroxychloroquine Small molecule 200 mg Oral

Indications